Hansa Biopharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	189.46	222.27	171.32
Revenue Growth (YoY)	10.59%	29.74%	-
Cost of Revenue	81.14	83.56	83.55
Gross Profit	108.32	138.71	87.76
Selling, General & Admin	414.52	356.55	344.27
Research & Development	269.85	304.74	375.72
Other Operating Expenses	13.31	-1.87	5.65
Total Operating Expenses	697.68	659.42	725.64
Operating Income	-589.36	-520.71	-637.88
Interest Income	40.9	170.8	20.83
Interest Expense	-173.94	-122.49	-187.17
Other Non-Operating Income (Expense)	-30.53	-59.45	-
Total Non-Operating Income (Expense)	-163.57	-11.13	-166.33
Pretax Income	-752.93	-531.84	-804.21
Provision for Income Taxes	2.22	2.27	3.03
Net Income	-755.14	-534.11	-807.24
Net Income to Common	-755.14	-534.11	-807.24
Shares Outstanding (Basic)	98	81	63
Shares Outstanding (Diluted)	98	81	63
Shares Change (YoY)	55.19%	29.23%	-
EPS (Basic)	-7.86	-6.58	-12.85
EPS (Diluted)	-7.86	-6.58	-12.85
Free Cash Flow	-579.63	-549.17	-675
Free Cash Flow Per Share	-5.94	-6.76	-10.74
Gross Margin	57.17%	62.41%	51.23%
Operating Margin	-311.07%	-234.27%	-372.34%
Profit Margin	-398.58%	-240.30%	-471.20%
FCF Margin	-305.94%	-247.08%	-394.01%
EBITDA	-589.36	-481.96	-609.82
EBITDA Margin	-311.07%	-216.84%	-355.96%
EBIT	-589.36	-520.71	-637.88
EBIT Margin	-311.07%	-234.27%	-372.34%
Effective Tax Rate	-0.29%	-0.43%	-0.38%